Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-537-2_3

Chapter 3: Nanotheranostics: Integrating Diagnosis and Therapy in Breast Cancer Management

Pritam Kayal[1], Doneparthi Mihir Medhansh[2], Bipasha Pal[3], Mohankumar Ramar[4], Ramit Rahaman[5], N. Jawahar[2]*

[1]Department of Pharmaceutics, Bharat Pharmaceutical Technology, Agartala, Tripura-799130, India.
[2]Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Nilgiris, Tamil Nadu, 643001, India.
[3]Department of Pharmacognosy, Gupta college of technological science, Asansol, West Bengal 713303
[4]Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, USA
[5]Department of Pharmaceutics, Guru Nanak Institute of Pharmaceutical Science & Technology, Sodepur, Kolkata 700110, India

Correspondence Author
*Dr. Natarajan Jawahar**
Email: jawahar.n@jssuni.edu.in

Abstract

Nanotheranostics represents a paradigm-shifting approach in breast cancer management, integrating diagnostic imaging and therapeutic delivery within multifunctional nanoscale platforms to overcome limitations of conventional sequential treatment strategies. This comprehensive field encompasses diverse nanocarrier systems including liposomes, polymeric nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), and gold nanostructures that exploit enhanced permeability and retention (EPR) effects for tumor-specific accumulation while minimizing systemic toxicity. Advanced nanotheranostic platforms incorporate stimuli-responsive release mechanisms triggered by pH, temperature, or enzymatic activity, enabling controlled delivery of chemotherapeutics (doxorubicin, paclitaxel), photosensitizers, and genetic materials (siRNA, CRISPR/Cas9) with real-time monitoring capabilities. Contemporary imaging modalities integrated within these systems include magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and fluorescence imaging, facilitating simultaneous visualization of biodistribution, therapeutic response, and resistance development. Therapeutic strategies encompass photodynamic therapy (PDT), photothermal therapy (PTT), magnetic hyperthermia, immunotherapy enhancement, and combination chemotherapy approaches that demonstrate superior efficacy compared to monotherapy regimens. Clinical successes include FDA-approved formulations such as Doxil® and Abraxane®, while emerging platforms focus on triple-negative breast cancer interventions and HER2-targeted approaches. Despite extraordinary therapeutic potential, significant challenges in manufacturing scalability,

regulatory complexity, safety concerns for biocompatibility, and ultra-high development costs that need multidisciplinary collaboration exist. Future directions emphasize the integration of artificial intelligence, biomimetic cell-derived nanocarriers, personalized medicine approaches, and standardization of assessment methods for improved clinical translation. Global expansion of the nanomedicine industry emphasizes the revolutionary potential of nano-theranostics in revolutionizing precision oncology.

Keywords: *Nanotheranostics, Superparamagnetic iron oxide nanoparticles SPIONs, Breast cancer, Targeted therapy, Multimodal imaging, Biomimetic.*

1 Introduction to Nanotheranostics in Breast Cancer

The convergence of nanotechnology with therapeutic and diagnostic methods has sparked a profound change in the treatment of cancer, and particularly in the treatment of breast cancer. This change in direction represents a profound shift away from traditional sequential methods, by which diagnosis and therapy operate autonomously, toward combined platforms that simultaneously achieve the one while executing the other within a holistic system. The development of nanotheranostics as a field is indicative of an academic agreement that the successful management of cancer requires not just a precise diagnosis or a powerful therapy alone, but a cohesive integration of both functions in a way that leads to the optimal patient outcomes[*Kim, et al., 2013*].

1.1 Defining Nanotheranostics

The term "theranostics" is a blend between "therapeutic" and "diagnostic" and describes the simultaneous blending of diagnosis and treatment into comprehensive systems. Nanotheranostics capitalizes on the properties of nanomaterials in order to engineer multi-functional platforms for enabling targeted delivery, real-time feedback, and therapy at the nano-scale level. This is a new paradigm from 'diagnose-then-treat' and 'diagnose-and-treat-separately' approaches to an integrated 'diagnose-and-treat-simultaneously' methodology.

Nanotheranostic systems overcome shortcomings of traditional methods in that diagnostic and therapeutic protocols function autonomously with gaps in timing. State-of-the-art platforms combine several functionalities in a single system of nanocarrier (5-200 nm), taking advantage of special biological pathways not open to conventional bulk drug delivery systems [*Roma-Rodrigues, et al., 2019*].

1.2 Fundamental Principles of Simultaneous Diagnosis and Therapy

The fundamentals involved in nanotheranostics include the concomitant co-delivery of imaging molecules and drugs by engineered nanocarriers that have the capacity for penetration of biological barriers, selective targeting of disease-involved sites, and timely indication of treatment efficacy. Imaging agents, therapeutic agents (eg. chemotherapeutics, photosensitizers or radionuclides), and imaging agents (eg. fluorescent dyes, quantum dots, magnetic-resonance contrast agents or radionuclides) are routinely incorporated into such systems. The main design principle implies the

development of multifunctional nanoparticles that may: (1) evadeimmune clearance by reducing their surface area with PEGylation; (2) target tumors by employing the enhanced permeability and retention (EPR) effect or active targeting conjugations; (3) monitor biodistribution and treatment effects in real-time by providing diagnostic signals on the surface; and (4) deliver therapeutic agents with regulated release kinetics. This combined strategy allows clinicians to imagine how the drugs diffuse, determine treatment effect and modify treatment regimens as a result of instant feedback, which is an important improvement over traditional treatment models [*Vasseur, 2024*],[*World Health Organization, 2024*].

1.3 Limitations of Conventional Imaging and Treatment Approaches

Traditional breast-cancer imaging techniques such as mammography, ultrasound and magnetic-resonance imaging (MRI) are burdened with low precision and limited functionality. Mammography's effectiveness drops sharply in dense breasts, with sensitivity as low as 48% and only moderate specificity, resulting in many false positives. MRI offers high sensitivity (>90%) but also high false-positive rates, cost, limited access and safety concerns over gadolinium contrast. Ultrasound aids dense-tissue evaluation yet remains operator-dependent and may miss small metastases [*Fumagalli, et al., 2021*], [*Nissan, et al., 2024*].

Standard treatments mirror these shortcomings. Chemotherapy often leads to resistance, biomarker instability and severe off-target toxicity, especially in aggressive subtypes like triple-negative breast cancer, underscoring the need for more precise therapeutic strategies.



Figure 3.1 Conceptual illustration comparing conventional sequential diagnosis-treatment approach versus integrated nanotheranostic platform **(Source: BioRender)**

2.1 Core Components of Nanotheranostic Systems

Table 3.1 Smart Nanocarrier Platforms for Breast Cancer Theranostics

Nanocarrier Type	Size Range (nm)	Targeting Mechanism	Therapeutic Payload	Imaging Modality	Clinical Status	Key Advantages
Liposomes	50-200	EPR + Active targeting	Doxorubicin, Paclitaxel	MRI, Fluorescence	FDA Approved (Doxil®)	High biocompatibility, dual cargo loading
Polymeric NPs	10-300	pH-responsive, enzyme-triggered	Chemotherapeutics, siRNA	PET, SPECT	Phase II/III trials	Controlled release, biodegradable
Gold NPs	5-100	Photothermal activation	Photosensitizers	CT, PAI	Preclinical	Plasmonic properties, dual PTT/imaging
Iron Oxide (SPIONs)	10-50	Magnetic targeting	Hyperthermia agents	MRI T1/T2 contrast	Phase I trials	Magnetic guidance, excellent MRI contrast
Upconversion NPs	20-80	Glycopeptide targeting	Dox + anti-Bcl2 siRNA	NIR-II imaging	Preclinical	Triple therapy capability, deep penetration
Carbon Nanozymes	15-40	ROS-mediated activation	Catalase-like enzymes	Fluorescence	Preclinical	Enzyme-like activity, enhanced radiosensitization

Table 3.2 Advanced Targeting Strategies in Nanotheranostics

Targeting Strategy	Target Receptors	Ligand Type	Mechanism	Efficacy (%)	Breast Cancer Subtype	Recent Innovation
Active Targeting	HER2, EGFR	Monoclonal antibodies	Receptor-mediated endocytosis	85-95	HER2+, TNBC	^{89}Zr-trastuzumab PET imaging
Charge-Reversal	TME pH (6.5-7.0)	pH-sensitive polymers	Surface charge switching	90-95	All subtypes	TPRN-CM with r9 peptide
Enzyme-Responsive	MMPs, Cathepsins	Cleavable peptides	Enzymatic drug release	80-90	Metastatic	MMP-cleavable linkers
Biomimetic	CD47, membrane proteins	Cell membrane coating	Immune evasion	75-85	TNBC	RBC membrane camouflage
Dual Targeting	Fn14 + Integrin	DART particles	Synergistic binding	95+	TNBC	Superior to Abraxane®
Glyco-targeting	Glucose transporters	Glucose conjugates	Enhanced cellular uptake	80-92	All subtypes	Glyconanoprobes

Table 3.3 Multimodal Imaging Integration

Imaging Combination	Contrast Agents	Penetration Depth	Resolution	Sensitivity	Clinical Application	Recent Breakthrough
MRI + CT	Fe_3O_4 + Au nanocages	Unlimited	Sub-mm	90-98%	Deep tissue monitoring	Dual T1-T2 enhancement
PET + MRI	^{64}Cu-DOTA + SPIONs	Unlimited	1-2 mm	95-99%	Metabolic + anatomical	Long-lived isotope tracking
PAI + Ultrasound	Gold nanorods + microbubbles	3-7 cm	50-200 μm	85-92%	Real-time drug release	Collagen-specific detection
Fluorescence + MRI	NIR dyes + Gd chelates	1-5 cm	1-10 μm	80-95%	Surgical guidance	NIR-II window imaging
Triple Modal	UCNPs + Fe_3O_4 + Dyes	Variable	Multi-scale	90-95%	Comprehensive monitoring	Single platform integration

Table 3.4 AI-Enhanced Nanotheranostic Design and Optimization

AI Application	ML Algorithm	Dataset Type	Optimization Target	Performance Improvement	Timeline Reduction	Clinical Impact
NP Design	Deep Neural Networks	Physicochemical properties	Cellular uptake efficiency	15-fold increase	2 iterations vs 10+	Rapid formulation screening
Targeting Prediction	Random Forest + SVM	Multi-omics data	Treatment response	98% accuracy	4-6 months earlier detection	Personalized therapy selection
Imaging Analysis	CNNs (ResNet50, VGG19)	Medical imaging	Diagnostic accuracy	33% improvement	Real-time processing	Automated diagnosis
Drug Release	Bayesian Optimization	Kinetic profiles	Release rate control	90% precision	1 week design cycle	Optimal dosing strategies
Resistance Detection	Radiomics + DL	Longitudinal imaging	Early resistance markers	91% AUC	2-4 months advance warning	Proactive treatment switching

Biomarker Discovery	Ensemble Methods	Genomic + Proteomic	Prognostic signatures	94% validation accuracy	Months to weeks	Precision medicine implementation

Table 3.5 Stimuli-Responsive Release Mechanisms

Stimulus Type	Trigger Condition	Release Mechanism	Response Time	Drug Examples	Selectivity	Clinical Advantage
pH-Responsive	TME acidic (pH 6.5)	Acid-labile linkers	Minutes	Doxorubicin, MTX	10-fold selectivity	Reduced systemic toxicity
Enzyme-Triggered	MMP overexpression	Peptide cleavage	Hours	Paclitaxel, Gemcitabine	15-fold selectivity	Tumor-specific activation
Temperature	Hyperthermia (40-45°C)	Phase transition	Seconds	Cisplatin, Carboplatin	Spatial precision	Localized drug release
Light-Activated	NIR irradiation (808 nm)	Photochemical reaction	Seconds	Photosensitizers	On-demand control	Non-invasive activation
Magnetic Field	External magnetic field	Magnetothermal heating	Minutes	Magnetic hyperthermia	Targeted heating	Deep tissue penetration
Redox-Responsive	GSH concentration (mM)	Disulfide bond cleavage	Minutes	Anti-cancer drugs	Intracellular specificity	Cytoplasmic drug release

Table 3.6 Clinical Translation and Regulatory Status

Nanotheranostic Platform	Clinical Phase	Study Population	Primary Endpoint	Results	Market Projection
Liposomal Doxorubicin	Marketed	Metastatic BC	Overall survival	Approved efficacy	$2.1B by 2028
Albumin-bound Paclitaxel	Marketed	TNBC	Progression-free survival	Standard of care	$1.8B by 2027
SPION-based Contrast	Phase III	All subtypes	Imaging sensitivity	95% sensitivity	$850M by 2026
HER2-targeted ADCs	Phase II/III	HER2+ BC	Tumor response rate	78% response rate	$3.2B by 2030
AI-guided Nanoplatforms	Phase I	Selected patients	Safety and efficacy	Ongoing enrollment	$500M by 2025
Theranostic Radiopharmaceuticals	Phase II	Bone metastases	Pain reduction + imaging	Promising results	$1.2B by 2029

Table 3.7 Future Perspectives and Emerging Technologies

Innovation Area	Technology	Development Stage	Expected Impact	Key Players	Investment Focus
AI-NP Integration	Machine learning-guided design	Early clinical	Personalized nanoformulations	Academia + Big Pharma	$2.5B projected
Biomimetic Systems	Cell membrane coating	Preclinical	Enhanced immune evasion	Biotech startups	$800M funding
Quantum Dots	Advanced imaging probes	Research phase	Single-cell resolution	Tech companies	$1.2B investment
CRISPR-NPs	Gene editing delivery	Preclinical	Precision gene therapy	Gene therapy firms	$3.0B market
Wearable Nanosensors	Real-time monitoring	Prototype	Continuous health tracking	Device manufacturers	$500M development
4D Nanoprinting	Spatiotemporal control	Research	Dynamic drug release	3D printing industry	$200M research

3 Conventional Imaging Enhancement

3.1 Mammography and Digital Breast Tomosynthesis Improvements

Digital breast tomosynthesis (DBT) significantly improves on mammography in dense tissue by acquiring limited-angle projections to reconstruct 3D images, reducing overlap artifacts. The TOSYMA trial (99,689 women) reported up to 44% higher cancer detection with DBT plus synthesized mammography. AI-augmented DBT platforms (e.g., Transpara 1.7.0, ProFound AI 3.0) further enhance diagnostic accuracy. Contrast-enhanced DBT using dual-energy subtraction visualizes vascular changes, aiding nanotheranostic monitoring while lowering radiation dose in dense breasts [*Philpotts, et al., 2024*].

3.2 Ultrasound Contrast Enhancement and Elastography Applications

Ultrasound elastography characterizes tissue mechanical properties with exceptional diagnostic performance, achieving sensitivities of 94.0% to 97.0% and specificities of 86.0% to 90.7% for breast lesion differentiation. Elastography techniques, including strain and shear wave elastography, provide quantitative tissue stiffness assessment correlating with nanotheranostic-induced pathological changes. Shear wave elastography shows particular promise, with elastic modulus measurements exceeding 92.80 kPa indicating malignant tissue.

Contrast-enhanced ultrasound (CEUS) enables real-time nanotheranostic monitoring using microbubble contrast agents that enhance tumor vasculature and perfusion visualization. Advanced ultrasound-guided photoacoustic imaging provides simultaneous assessment of tissue composition including collagen, lipid, and

hemoglobin distribution. Studies demonstrate significant collagen intensity differences between cancerous and normal breast tissue ($P < 0.001$), providing biomarkers for nanotheranostic targeting and response assessment [*Negrão de Figueiredo, et al., 2019*].

3.3 MRI Contrast Agents and Functional Imaging

MRI offers superb soft-tissue contrast; advanced agents (gadolinium, iron oxide nanoparticles) track nanoparticle biodistribution. Diffusion-weighted (DWI) and dynamic contrast-enhanced (DCE) MRI reveal cellularity and perfusion changes tied to therapeutic response. SPIONs provide both drug delivery and real-time T2 signal monitoring, while responsive agents adjust contrast in response to pH or enzyme activity. [*Philpotts, et al., 2024*].

4 Advanced Imaging Technologies

4.1 PET/CT and Molecular Imaging Approaches

Positron emission tomography combined with computed tomography (PET/CT) has emerged as a cornerstone technology for molecular imaging in nanotheranostic applications, providing quantitative assessment of metabolic activity and target expression with unlimited tissue penetration. Contemporary ^{18}F-FDG PET/CT protocols demonstrate sensitivities of 85% to 95% and specificities of 80% to 90% for breast cancer detection and staging, with particular utility in triple-negative and HER2-positive subtypes. The integration of long axial field-of-view (LAFOV) PET/CT scanners has substantially improved sensitivity for immunoPET applications, enabling enhanced visualization of antibody-drug conjugates and targeted nanotheranostics.

HER2-targeted PET/CT imaging represents a significant advancement in personalized nanotheranostic monitoring, utilizing radiolabeled antibodies, antibody fragments, and nanobodies to assess target expression and therapeutic response. Recent clinical studies with ^{89}Zr-trastuzumab and ^{64}Cu-DOTA-trastuzumab demonstrate sensitivities of 88% to 98% and specificities of 85% to 95% for HER2 expression assessment, enabling patient stratification for HER2-targeted nanotheranostics. Advanced molecular probes including ^{68}Ga-DOTATATE for somatostatin receptor imaging and ^{68}Ga-Trivehexin for integrin targeting provide additional options for nanotheranostic monitoring and treatment selection.

Radiomics approaches utilizing PET/CT imaging data have demonstrated significant potential for predicting treatment response and prognosis in breast cancer patients. Recent studies incorporating 704 radiomics features with clinical characteristics achieve area under the curve values of 0.90 for Ki67 expression prediction, enabling personalized nanotheranostic treatment protocols. The integration of artificial intelligence and machine learning algorithms with PET/CT data analysis provides enhanced capabilities for early response assessment and treatment optimization [*Brouwers, et al., 2022*].

4.2 Fluorescence and Optical Imaging Techniques

Near-infrared (NIR) fluorescence imaging enables real-time nanotheranostic monitoring with high sensitivity (80–95%) and penetration depths of 1–5 cm, suitable for tracking nanoparticle biodistribution and therapeutic response in breast lesions. Advanced systems use activatable probes and FRET-based mechanisms for direct visualization of drug release and treatment efficacy, achieving spatial resolutions of 1–10 micrometers. Optical coherence tomography (OCT) further provides cellular-level imaging (1–10 μm resolution) for detailed tissue characterization, especially when integrated with other optical modalities [*Brouwers, et al., 2022*].

4.3 Photoacoustic Imaging and Multimodal Approaches

Photoacoustic imaging merges optical sensitivity with ultrasound depth, offering 85–92% sensitivity and 3–7 cm penetration. It assesses biochemical markers (collagen, lipids, hemoglobin) and uses targeted contrast agents for molecular-specific imaging, supporting precise nanotheranostic monitoring. Multimodal imaging combines techniques (e.g., magnetic resonance, optical, photoacoustic) within single platforms, achieving sensitivities of 90–98% and specificities of 85–95%. These integrated systems, often enhanced by machine learning, allow comprehensive assessment of biodistribution, therapeutic response, and resistance, while universal contrast agents simplify monitoring across modalities [*Brouwers, et al., 2022*].

5 Real-time Monitoring Capabilities

5.1 Treatment Response Assessment

Real-time treatment response assessment represents a critical advantage of nanotheranostic systems, enabling Reporter nanoparticles with stimuli-responsive elements give immediate feedback on therapy efficacy via imaging signal changes, detecting responses earlier than conventional modalities. Multiparametric imaging—combining anatomical, functional and molecular scans—plus ctDNA liquid biopsies enable personalized, real-time treatment adjustments. AI-driven analysis of multimodal data automates and standardizes response evaluation, identifying subtle changes before standard criteria and driving predictive models for optimized therapy [*Zaikova, E., et al., 2024*].

5.2 Biodistribution Tracking and Pharmacokinetic Monitoring

Comprehensive biodistribution tracking represents a fundamental requirement for nanotheranostic optimization, enabling quantitative assessment of nanoparticle accumulation, distribution, and clearance. Advanced imaging protocols utilize multiple modalities to provide detailed pharmacokinetic information including circulation time, tissue accumulation, and elimination pathways. Recent developments in mass cytometry provide label-free quantitation of inorganic nanoparticles at the single-cell level, enabling unprecedented insight into cellular uptake and biodistribution patterns.

Fused with imaging data, physiologicallybased pharmacokinetic (PBPK) models provide a more informative view on nanotheranostic behaviour and guide the optimisation of therapeutic regimens. Recent PBPK models include particle-specific

characteristics, including size, surface charge, and ligand density to determine biodistribution dynamics and resultant therapeutic efficacy. Clinicians can combine the effects of real-time imaging with PBPK constructs to develop adaptive treatment approaches that bring drug delivery to the individual pharmacokinetic profile of the individual patient. Long-term biodistribution monitoring uses the use of the superior imaging modalities to measure the nanoparticle persistence and potentially the accumulation in off-target tissues. Recent research employing ^{89}Zr-labeled monoclonal antibodies illustrates prolonged observation capabilities over a few days and thus allows for thorough evaluation of the biodistribution and clearance of antibody-drug conjugates. The technique of biodegradable imaging tracers contributes to the further improvement of safety profiles under repeated monitoring, thus satisfying the high requirements of the modern nanotheranostic procedures [*Brouwers, et al., 2022*].

5.3 Early Detection of Therapeutic Resistance

Early detection of therapeutic resistance represents a critical capability for nanotheranostic systems, enabling timely treatment modifications before resistance becomes established. The future imaging modalities use molecular markers of resistance such as biomarker of cancer stem cells, metabolic changes, and vascular remodelling to identify the emergence of resistance. Recent advances in cancer stem cell imaging have allowed the identification of treatment resistant cellular subpopulations that contribute to disease recurrence in a non-invasive manner.

Circulating tumor cell (CTC) surveillance provides complementary information to resistance detection, and state-of-the-art nanotheranostic systems have shown the ability to monitor and eliminate CTCs before the metastasis of cells. Surveys of CTCs using targeted nanotheranostics show that the circulation of tumor burden is reduced and a subsequent decrease in the spread of metastasis in the distant organs is observed. Combining CTC monitoring with the traditional imaging creates a complex evaluation of the resistance dynamics as well as the potential of metastases. Machine-learning algorithms can be used to identify the early signs of therapeutic resistance using adaptive imaging protocols based on identifying temporal changes in imaging. Modern applications make use of the radiomic methods to derive quantitative imaging characteristics which are linked to progression of the resistance thus supporting predictive modeling of treatment outcomes. Early intervention and therapeutic modulation have better prospects of being achieved through the establishment of resistance-specific imaging biomarkers [Dos Santos, *et al.*, 2025].

The evaluation of imaging modalities in nanotheranostic settings conducted systematically shows considerable differences in performance features, clinical usefulness and integration aspects of different technologies. The concept of the multimodal approach to imaging is gaining growing support in modern imaging practices, with the view of exploiting the advantages of a given modality and reducing the drawbacks associated with it. Choice of the best imaging regimen depends on the particular nanotheranostic application, target tissue characteristics, and monitoring

requirements, and individualized strategies of imaging have become the paradigm of care in precision nanomedicine [*Bonlawar, et al., 2024*].

5.4 Imaging Modalities and Diagnostic Capabilities

Combination of advanced imaging technologies and nanotheranostic systems is a paradigm shift in the management of breast cancer that allows real-time visualization of the administration of therapeutic agents, evaluation of therapeutic response, and early response to resistance mechanisms. Contemporary imaging approaches for nanotheranostics encompass both conventional modalities enhanced for nanomedicine applications and emerging technologies specifically designed for molecular imaging and real-time monitoring. The selection of appropriate imaging modalities depends on multiple factors including sensitivity requirements, penetration depth, spatial resolution, and compatibility with nanoparticle tracking. Modern nanotheranostic platforms increasingly incorporate multimodal imaging capabilities that combine anatomical, functional, and molecular information within single systems to provide comprehensive treatment monitoring[*Ming, et al., 2020*].

6 Conventional Imaging Enhancement



Figure 3.1 Illustration showing the nanotheranostic approach in targeted therapy for breast cancer (Source: BioRender)

6.1 Mammography and Digital Breast Tomosynthesis Improvements

Digital breast tomosynthesis (DBT) has emerged as a significant advancement over conventional digital mammography, demonstrating superior cancer detection rates particularly in women with dense breast tissue. Recent clinical trials, including the landmark TOSYMA study involving 99,689 women, have demonstrated that DBT plus synthesized mammography achieves significantly higher invasive cancer detection rates compared to digital mammography alone, with detection improvements of 32.6% to

43.6%. The technology utilizes a limited-angle tomographic approach, acquiring multiple low-dose projections through a 15-degree arc to reconstruct three-dimensional images that overcome tissue overlap limitations inherent in conventional mammography [*Sommer, et al., 2024*].

Contemporary DBT systems demonstrate enhanced performance metrics with sensitivities ranging from 82.8% to 97.0% and specificities of 88% to 95%, representing substantial improvements over conventional digital mammography sensitivities of 56.8% to 81.3%. The integration of artificial intelligence algorithms with DBT has further enhanced diagnostic performance, with FDA-cleared AI systems such as Transpara 1.7.0 and ProFound AI 3.0 demonstrating area under the curve values of 0.86 and 0.93 respectively for malignancy detection. Advanced DBT platforms now incorporate contrast-enhanced capabilities, utilizing dual-energy subtraction techniques to visualize vascular enhancement patterns that may indicate nanoparticle accumulation and therapeutic response.

The clinical utility of DBT for nanotheranostic applications extends beyond improved cancer detection to include enhanced visualization of tissue architectural changes following nanoparticle delivery. Recent studies have demonstrated that DBT can effectively monitor treatment-induced changes in breast density and vascular patterns, providing indirect assessment of nanotheranostic biodistribution. The reduced radiation dose requirements in dense breast tissue, with average glandular doses declining from 2.41 mGy in fatty breasts to 1.89 mGy in extremely dense breasts, make DBT particularly suitable for repeated monitoring applications required in nanotheranostic protocols [*Goh, et al., 2024*].

6.2 Ultrasound Contrast Enhancement and Elastography Applications

Ultrasound elastography has evolved as a powerful tool for characterizing tissue mechanical properties, achieving exceptional diagnostic performance with sensitivities of 94.0% to 97.0% and specificities of 86.0% to 90.7% for breast lesion differentiation. Contemporary elastography techniques, including strain elastography and shear wave elastography, provide quantitative assessment of tissue stiffness that correlates with pathological changes induced by nanotheranostic interventions. Shear wave elastography demonstrates particular promise for nanotheranostic monitoring, with elastic modulus measurements exceeding 92.80 kPa serving as reliable indicators of malignant tissue that may respond differently to nanoparticle-based therapies.

Contrast-enhanced ultrasound (CEUS) represents a significant advancement in real-time nanotheranostic monitoring, utilizing microbubble contrast agents that enhance visualization of tumor vasculature and perfusion patterns. Recent implementations of CEUS demonstrate sensitivities and specificities approaching 100% for gallbladder pathology assessment, suggesting similar potential for breast cancer applications. The technology enables real-time assessment of nanoparticle biodistribution through enhanced visualization of tumor vasculature and perfusion changes that accompany successful nanotheranostic delivery.

Advanced ultrasound-guided photoacoustic imaging systems have demonstrated significant potential for nanotheranostic applications, providing simultaneous assessment of tissue composition including collagen, lipid, and hemoglobin distribution [*Tao, et al., 2022*][*Elahi, et al., 2024*]. Recent studies utilizing handheld ultrasound-photoacoustic probes on ex-vivo breast specimens have shown that collagen intensity differs significantly between cancerous and normal breast tissue ($P < 0.001$), providing additional biomarkers for nanotheranostic targeting and response assessment. The integration of multiple acoustic contrast mechanisms enables comprehensive tissue characterization that can guide nanotheranostic design and monitor therapeutic efficacy [*Goh, et al., 2024*].

6.3 MRI Contrast Agents and Functional Imaging

Magnetic resonance imaging represents the gold standard for breast cancer detection and monitoring, achieving sensitivities of 88% to 100% with excellent soft tissue contrast capabilities. Contemporary MRI protocols for nanotheranostic applications utilize advanced contrast agents including gadolinium-based compounds and iron oxide nanoparticles that provide enhanced T1 and T2 contrast for tracking nanoparticle biodistribution. Recent developments in contrast-enhanced MRI demonstrate sensitivities of 90% to 98% and specificities of 80% to 92% for perfusion assessment, enabling precise monitoring of nanotheranostic delivery and response.

Functional MRI techniques including diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI provide critical information about tissue microstructure and perfusion that correlates with nanotheranostic efficacy. DWI sequences enable assessment of tissue cellularity changes following nanotheranostic intervention, with apparent diffusion coefficient measurements serving as early biomarkers of treatment response. DCE-MRI schemes can be used to determine the quantitative perfusion and permeability of tissues, thus being able to directly visualize the enhanced permeability and retention (EPR) effect of passive nanoparticle targeting. The latest MRI contrast reagents designed with nanotheranostic uses include superparamagnetic iron oxide nanoparticles (SPIONs), which have dual-purpose as therapeutic delivery systems and as imaging contrast agents. Recent studies demonstrate that SPION-based nanotheranostics enable real-time MRI monitoring of drug delivery and therapeutic response, with T2 signal changes correlating directly with nanoparticle accumulation and drug release. A significant milestone for the potential of nanotheranostic imaging is the development of responsive MRI contrast agents that adaptively modify their signal characteristics in relation to a specific condition of biological origin, e.g., pH or change in enzyme activity [*Wang, et al., 2023*].

7 Advanced Imaging Technologies

7.1 PET/CT and Molecular Imaging Approaches

Positron emission tomography and computed tomography (PET/CT) has become a core technology of molecular imaging for applications in nanotheranostics by allowing

quantitative assessments of target expression and metabolic activity with unlimited tissue penetrations. State-of-the-art ^{18}F-FDG PET/CT protocols have sensitivities of 85%-95% and specificities of 80%-90% for staging and detection of breast cancer and show special potency for triple-negative and HER2-positive variants. The addition of long axial field-of-view (LAFOV) PET/CT scanners has dramatically improved sensitivity for applications in immunoPET, thus enabling enhanced visualization of targeted nanotheranostics and antibody-drug conjugates.

Radiomics approaches utilizing PET/CT imaging data have demonstrated significant potential for predicting treatment response and prognosis in breast cancer patients. Recent studies incorporating 704 radiomics features with clinical characteristics achieve area under the curve values of 0.90 for Ki67 expression prediction, enabling personalized nanotheranostic treatment protocols. The integration of artificial intelligence and machine learning algorithms with PET/CT data analysis provides enhanced capabilities for early response assessment and treatment optimization [*Shamir, et al., 2024*].

7.2 Fluorescence and Optical Imaging Techniques

Near-infrared (NIR) fluorescence imaging has proven a useful tool for real-time monitoring of nanotheranostics, with excellent sensitivity and temporal resolution for nanoparticle biodistribution and therapeutic response. Modern fluorescence imaging systems attain sensitivities of 80% to 95% and penetration depths of 1 to 5 cm, and can visualize superficial and relatively deep breast lesions. High-performance fluorescent nanotheranostics have built-in activatable probes that change from weakly fluorescent or dark states to highly fluorescent states upon release of a drug or ligand binding to a target, allowing for direct visualization of therapeutic activation.

Self-quenching fluorescent systems are a notable milestone in the history of nanotheranostic monitoring by employing FRET-based systems for real-time feedback of drug release and therapeutic responses. Recent developments include sequence-activated fluorescent nanotheranostics that provide dual-channel NIR outputs for monitoring biodistribution and cellular uptake in sequential fashion. These systems enjoy unparalleled versatility for delineation of tumor margins and treatment responses, achieving spatial resolutions of nearly 1 to 10 micrometers.

Optical coherence tomography (OCT) provides ultra-high resolution imaging capabilities with spatial resolutions of 1 to 10 micrometers, enabling cellular-level visualization of nanotheranostic interactions. Advanced OCT systems demonstrate sensitivities of 90% to 95% and specificities of 85% to 95% for tissue characterization, though penetration depths are limited to 1 to 3 millimeters. The integration of OCT with other optical imaging modalities enables comprehensive assessment of surface and subsurface nanotheranostic effects [*Shamir, et al., 2024*].

7.3 Photoacoustic Imaging and Multimodal Approaches

Photoacoustic imaging combines the high sensitivity of optical imaging with the deep penetration capabilities of ultrasound, achieving sensitivities of 85% to 92% and penetration depths of 3 to 7 centimeters. Recent implementations utilizing handheld ultrasound-guided photoacoustic probes demonstrate exceptional potential for nanotheranostic monitoring through assessment of biochemical markers including collagen, lipids, and hemoglobin. Advanced photoacoustic systems enable molecular-specific imaging through the use of targeted contrast agents that enhance signal generation upon nanoparticle binding or activation [*Goh, et al., 2024*].

Multimodal imaging approaches represent the optimal strategy for comprehensive nanotheranostic monitoring, combining multiple imaging techniques within integrated platforms. Contemporary multimodal systems achieve sensitivities of 90% to 98% and specificities of 85% to 95% through synergistic integration of complementary imaging modalities. Some of the recent examples encompassed nano-theranostic platforms that combine magnetic resonance, optical, and photoacoustic components of imaging under a single formulation that allows for simultaneous explorations of biodistribution, therapeutic effect, and development of resistance.

Multimodality imaging advanced methods adopt machine learning algorithm for the combination of data from different imaging sources for improved diagnostic precision and the ability for monitoring treatments. A major innovation in the use of nanotheranostic monitoring has been the development of generic contrast agents for signal enhancement for multiple imaging modalities that lower complexity and enhance the efficacy of diagnostics[*Xue, et al., 2018*].

8 Real-time Monitoring Capabilities

8.1 Treatment Response Assessment

In-time feedback on therapeutic response is a relevant benefit of nanotheranostic systems, which allows therapeutic regimens to be dynamically optimised by monitoring therapeutic effects in real-time. Modern reporter nanoparticles are developed with stimuli-responsive biomolecules that provide real-time feedback through stimulation of imaging signal intensity or spatial distribution. Recent studies identify that these reporter nanotheranostics are capable of detecting therapeutic response on acute temporal junctions whereby traditional imaging systems, e.g., 18F 2DG PET/CT, depict limited sensitivity [*Kulkarni, et al., 2016*].

The use of multiparametric imaging involving anatomical, functional, and molecular data to provide a complete evaluation of treatment efficacy is a strategy of advanced response assessment. The analysis of circulating tumour DNA (ctDNA) serves as additional data; the research shows that patients, with an incomplete pathological response and a positive ctDNA, have an exceptionally high risk of the disease progression. Combination of imaging-based metrics of response and liquid-biopsy techniques aid in personalised treatment modification based on real time monitoring.

Treatment response evaluation Artificial-intelligence algorithms complement multimodal imaging evaluation through automation of multimodal data analysis, and provide standardised and reproducible measurements of treatment efficacy. Modern applications use paradigms of deep-learning to identify subtle changes in imaging that occur before traditional response thresholds and detect the success or failure of treatment more quickly. Imaging biomarkers are also incorporated into predictive models that include clinical parameters in order to provide a better ability to predict response and optimise therapeutic strategies [*Shamir, et al., 2024*].

8.2 Biodistribution Tracking and Pharmacokinetic Monitoring

Systematic biodistribution tracking is needed for the optimization of nanotheranostics so that nanoparticle accumulation, dispersion, and clearance can be measured quantitatively. Multimodality imaging techniques use a variety of modalities for giving comprehensive pharmacokinetic data, such as circulation half-life, tissue residence, and clearance routes. The recent developments in the mass cytometry can label-free quantify inorganic nanoparticles at the single cell scale, providing unprecedented insight into patterns of cellular uptake and biodistribution of these materials at a single cell scale [*Yang, et al., 2017*]

Combined with imaging information, physiologically-based pharmacokinetic (PBPK) models provide a better insight into nanotheranostic behaviour and can guide the maximization of treatment regimens. Recent PBPK models include nanoparticle-specific parameters (size, surface charge, targeting ligand density, and others) to model biodistribution and therapeutic response. Combining real-time imaging information with PBPK models can be used to implement adaptive treatment programs that can fit drug delivery according to the pharmacokinetics of specific patients. Long-term biodistribution studies make use of advanced imaging methods to determine the persistence and possible accumulation of nanoparticles in tissues other than the target. The current research that uses 89Zr-labeled monoclonal antibodies allows measurement of biodistribution and clearance of antibody-drug conjugates over several days, thus allowing a robust evaluation of biodistribution and clearance of antibody-drug conjugates. Biodegradable imaging tracers also enhance the safety profile of repeated monitoring that is necessary in the nanotheranostic protocols [Moss, *et al*., 2014].

8.3 Early Detection of Therapeutic Resistance

Early detection of resistance to therapy is a central characteristic of nanotheranostic systems, which enables timely therapeutic adjustments, which can be made before the resistance becomes clinically apparent. More sophisticated imaging methods question molecular resistance biomarkers such as cancer stem cell biomarkers, metabolic changes, and angiogenic remodeling, to identify new resistance phenotypes. Recent advances of imaging of cancer stem cells enable non-invasive identification of treatment-resistant subpopulations that propagate disease recurrence. Circulating tumour cell (CTC) monitoring provides support information to detect resistance. Modern

nanotheranostic platforms show the capability to monitor and eliminate CTCs before metastatic colonisation as results of studies of targeted nanotheranostics which significantly decrease the circulating tumour burden and lower distant organ metastasis following treatment. A combination of CTC surveillance and standard imaging will provide a full evaluation of resistance evolution and the possibility of metastasis. Adaptive imaging protocols are machine-learning algorithms to identify early signs of therapeutic resistance by analysing temporal changes in imaging. Recent applications have involved radiomic approaches to extract quantitative information about imaging data that is associated with the development of resistance, allowing treatment outcomes to be predicted. Early intervention and adaptation of treatment is improved with the development of resistance-specific imaging biomarkers. The tedious assessment of imaging modalities in nanotheranostic applications demonstrates significant difference in performance features, clinical, and integration capabilities across a variety of technologies. The ongoing imaging approaches are increasingly supporting multimodal techniques that combine the benefits of the separate modalities by offsetting the limitations of the respective modalities. The choice of most effective imaging protocols depends on certain nanotheranostic uses, the properties of the target tissue and monitoring needs; patient-specific imaging approaches are thus becoming the standard of care in precision nanomedicine [Dhandapani, *et al*., 2023].

8.4 Artificial Intelligence and Machine Learning Integration

Introducing artificial intelligence (AI) and machine-learning (ML) technologies into nano-theranostic systems is a paradigm shift in the management of breast-cancer, and can afford it unprecedented accuracy in diagnosis, treatment-optimisation and personalised therapy delivery. Present-day AI-related systems have gone far beyond primitive pattern recognition, including more advanced deep-learning models that are able to handle multimodal data streams and provide real-time clinical decision support. The intersection of AI and nanotechnology has spawned intelligent therapeutic systems that will change behaviour based on the patient specificities, therapeutic reaction and changing tumour biology. Contemporary ML systems exhibit impressive performance improvements in breast-cancer tasks, and some achieves accuracy scores on diagnostic tasks over 98 % [Li, *et al*., 2016].

9 AI-Enhanced Diagnostic Capabilities

9.1 Deep Learning for Imaging Analysis and Pattern Recognition

Deep learning has transformed breast cancer imaging by automating image interpretation with expert-level accuracy. Modern convolutional neural networks (e.g., ResNet50, VGGNet, EfficientNet) analyze mammography, ultrasound and MRI—leveraging transfer learning and ensemble methods—to boost classification performance and cut false positives. Explainable AI overlays heatmaps and feature attributions onto images, making decisions transparent and enabling continuous model refinement with new clinical data. These AI frameworks deliver rapid, standardized diagnostics and

support real-time feedback, paving the way for more precise, data-driven clinical decisions[*Tao, et al., 2022*][*Mastrantoni, et al., 2024*].

9.2 Radiomics and Quantitative Imaging Biomarkers

Radiomics extracts hundreds of quantitative features—tumor shape, intensity and texture—from medical images to reveal subtle patterns invisible to the eye. Machine-learning–driven workflows select optimal feature sets for clinical tasks such as predicting treatment response or detecting resistance. For example, multi-zone peritumoral analysis (6 mm margin) outperforms intratumoral models in forecasting neoadjuvant chemotherapy outcomes. Integrated radiomics platforms combine MRI, mammography, contrast-enhanced spectral mammography, ultrasound and digital breast tomosynthesis, using AI to automate feature selection. Advanced radiomics now enables early resistance detection and real-time treatment monitoring to support adaptive nanotheranostic protocols [*Mastrantoni, et al., 2024*][*Elahi, et al., 2024*].

9.3 Automated Detection and Classification Systems

Automated detection systems now deploy lightweight deep learning and gradient-boosting models on mobile and point-of-care devices, delivering rapid, accurate breast cancer screening and classification. Platforms like Auto-BCS leverage efficient CNN backbones with XGBoost classifiers to balance speed and precision, while ensemble frameworks combining SVMs, random forests, and neural networks further boost robustness. AI-powered digital pathology tools analyze whole-slide images to characterize tumors and predict immune-metabolic subtypes, enabling personalized immunotherapy selection. Integrated multi-pipeline architectures achieve near-real-time diagnosis and treatment response forecasting, supporting seamless clinical decision support at the bedside[*Mastrantoni, et al., 2024*].

10 Treatment Optimization and Personalization

10.1 Predictive Modeling for Treatment Response

Machine-learning models now combine clinical, molecular and imaging data to stratify patients and forecast therapy outcomes—from median progression-free survival of 7.9 to 31.3 months. Techniques such as random survival forests and deep neural networks predict disease-free and overall survival (C-index ~0.68; AUC ~0.91 at 60 months). Real-time adaptive models—incorporating circulating biomarkers like non-coding RNAs and liquid biopsy profiles—enable on-the-fly treatment adjustments, enhancing prognostic accuracy and personalizing therapy decisions[*Cavazos, et al., 2024*].

10.2 Machine Learning for Nanoparticle Design Optimization

Machine learning (ML) accelerates nanoparticle formulation by linking computational prediction with automated experimentation. Microfluidic synthesis integrates high-content imaging and active ML to iterate designs, boosting cellular uptake up to 15-fold within two cycles. Bayesian optimization and neural networks predict ideal PLGA-PEG compositions, tailoring size, charge, and ligand density for breast cancer targeting. High-throughput ML workflows can finalize design cycles in under a week, systematically exploring vast formulation spaces. Advanced platforms now generate multifunctional

nanoparticles—combining imaging agents and therapeutics—guided by ML models that forecast biodistribution, uptake, and efficacy, streamlining development of next-generation nanotheranostics [*Ortiz-Perez, et al., 2024*].

10.3 Clinical Decision Support Systems

AI-driven decision support platforms synthesize EHRs, imaging, labs and patient-reported data to deliver real-time treatment recommendations and streamline workflows. Most systems demonstrate improved patient outcomes and higher adherence to evidence-based guidelines. Integrated order-entry and care-pathway modules reduce delays and disparities, benefiting underserved populations. Real-time monitoring and predictive analytics anticipate complications and enable dynamic therapy adjustments. Advanced platforms also parse unstructured records automatically, cutting administrative burden and enhancing clinical decision quality [*Choi, et al., 2024*][*Yu, et al., 2024*].

10.4 Personalized Medicine and Precision Therapy

Personalized medicine in breast cancer management has evolved into a sophisticated discipline that leverages individual patient characteristics, tumor biology, and treatment response patterns to optimize therapeutic outcomes. Contemporary precision therapy approaches integrate comprehensive biomarker analysis, advanced diagnostic technologies, and adaptive treatment protocols to deliver truly individualized care. The implementation of personalized medicine strategies has demonstrated significant improvements in treatment efficacy while reducing adverse effects through precise patient stratification and targeted therapeutic selection. Modern precision medicine frameworks utilize multi-dimensional data integration to account for the remarkable heterogeneity observed in breast cancer presentations and treatment responses [*Graetz, et al., 2024*][*Ghosh, et al., 2024*][*Obeagu, et al., 2024*].

11 Biomarker-Guided Therapy

11.1 Companion Diagnostics and Predictive Biomarkers

Companion diagnostics represent a cornerstone of personalized breast cancer therapy, providing essential information for treatment selection and patient stratification. Contemporary biomarker panels include estrogen receptor (ER), progesterone receptor (PR), Ki-67, and Human Epidermal growth factor Receptor 2 (HER2) as mandatory assessments for all breast cancer diagnoses. Recent consensus statements recommend BRCA gene testing in high-risk HER2-negative breast cancer to guide therapeutic decision-making and identify candidates for targeted therapies.

Sophisticated companion diagnostic techniques combine advanced biomarkers, such as phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and estrogen receptor 1 (ESR1) mutation, for the treatment of hormone-sensitive advanced breast cancer. Current testing techniques use comprehensive genomic profiling for the identification of actionable mutation, guiding the selection of precision therapy. Recent findings have unveiled tumor mutational burden (TMB) and microsatellite instability

(MSI) as strong predictive biomarkers for immunotherapy responses, and TMB ≥10 mutation/Mb has been found in 8-12% of cases of breast cancer.

Companion diagnostics have also encompassed liquid biopsy methods in recent times, allowing for non-invasive testing of biomarkers and real-time assessment of treatment responsiveness. Current platforms use analysis of the circulating tumor DNA for the detection of arising resistance mutations and therapy change guidance. Extended molecular imaging companion diagnostics offer additional data beyond that of tissue-based assays and allow for evaluation of biomarker heterogeneity at sites of metastases[Mankoff, *et al*., 2016].

11.2 Molecular Profiling and Treatment Selection

Extensive molecular profiling has now become a key component for the best treatment selection in breast cancer, and there are now four certified genetic prognostic platforms (Oncotype DX®, MammaPrint®, Prosigna®, and EndoPredict®) for clinical practice. Current molecular profiling methods use gene expression analysis for the creation of prognostic groupings and for ascertaining whether adjuvant treatment can be restricted to hormonal therapy for ER-positive patients. Recent literature illustrates that molecular profiling has the potential for selecting patients at low recurrence risk that may safely forgo chemotherapy and thus avoid overtreatment while preserving excellent outcomes. Advanced molecular profiling strategies incorporate multi-gene expression signatures that provide superior prognostic and predictive information compared to traditional single-biomarker approaches. Contemporary platforms analyze hundreds of genes simultaneously to create comprehensive molecular portraits that guide therapeutic decision-making. Recent developments include CRISPR-based functional profiling platforms that identify patient-specific therapeutic vulnerabilities independent of mutation status.

The integration of spatial transcriptomics and single-nucleus RNA sequencing enables detailed characterization of tumor microenvironment heterogeneity and identification of novel therapeutic targets. Contemporary molecular profiling approaches now incorporate analysis of ductal carcinoma in situ progression markers, including MGP, SLC39A6, PLAT, MLPH, AZGP1, TFF1, and TFF3, to predict invasion risk. Advanced profiling platforms demonstrate capability for real-time assessment of molecular changes during treatment, enabling dynamic therapeutic optimization [*Chen, et al., 2024*].

11.3 Pharmacogenomics and Drug Metabolism Variants

Pharmacogenomics represents a critical component of personalized breast cancer therapy, enabling optimization of drug selection and dosing based on individual genetic variations in drug metabolism. Contemporary pharmacogenomic approaches analyze genetic polymorphisms affecting drug efficacy and toxicity for key therapeutic agents including letrozole, anastrozole, tamoxifen, trastuzumab, and pertuzumab. Recent studies emphasize the importance of incorporating genetic testing into treatment planning to improve outcomes and reduce adverse reactions.

Advanced pharmacogenomic platforms utilize comprehensive genetic analysis to predict individual patient responses to specific therapeutic regimens. Contemporary approaches demonstrate that genetic variations significantly influence drug metabolism and treatment outcomes, necessitating personalized dosing strategies. The integration of pharmacogenomic data with clinical decision support systems enables real-time optimization of therapeutic protocols based on individual genetic profiles.

Modern pharmacogenomic applications extend beyond traditional drug metabolism genes to include analysis of immune system genetics and treatment response prediction. Contemporary platforms incorporate analysis of HLA typing and other immune-related genetic variants to optimize immunotherapy selection and predict adverse reactions. Advanced pharmacogenomic approaches now demonstrate capability for predicting combination therapy responses and optimizing multi-drug regimens based on individual genetic profiles [*Porfírio De Aguiar, 2023*].

12 Patient Stratification Strategies

12.1 Genomic Testing and Hereditary Risk Assessment

Multi-gene panels assess BRCA1/2 and other susceptibility genes, with tumor-normal sequencing distinguishing germline versus somatic mutations for treatment and counseling. Genetic risk scores offer prognostic insight beyond traditional factors, identifying individuals with doubled early-onset risk. Lifestyle counseling can reduce this risk by nearly half, and population-wide screening platforms now flag high-risk cases efficiently [*Roberts, 2018*].

12.2 Tumor Microenvironment Characterization

Multiplex immunofluorescence and spatial biology map biomarkers (CD8, FOXP3, PD-1/PD-L1) and quantify tumor-infiltrating lymphocytes to predict immunotherapy response, with spatial patterns informing prognosis. Real-time monitoring tracks microenvironmental shifts during therapy [*Lindsay, et al., 2025*].

12.3 Immune Profiling and Immunotherapy Selection

Comprehensive analysis of PD-L1, immune gene signatures, tumor mutational burden, and microsatellite instability identifies candidates for checkpoint inhibitors. Adaptive platforms enable ongoing immune status assessment to guide personalized immunotherapy [*Sivapiragasam, et al., 2021*].

12.4 Adaptive Treatment Protocols

Adaptive treatment protocols utilize circulating tumor DNA monitoring and AI-driven models to anticipate disease progression months before conventional imaging. These systems integrate clinical, genomic, and imaging data to optimize dose modulation and timing while maintaining efficacy and reducing toxicity. Moreover, detecting early resistance systems identify emerging mutations through ctDNA and genomic profiling, which allow the switch to different therapeutic options in good time and the optimisation of treatment plans. Patient-reported outcomes and shared decision-making processes embedded in these frameworks balance the intensity of treatment with the quality-of-life considerations, thus improving the adherence to treatment and reducing the rates of

hospitalization by offering real-time and personalised care [*Graetz, et al., 2024*], [*Karsten, et al., 2021*], [*Priskin, et al., 2021*].

Conclusion

Nanotheranostics is a game-changer for the treatment of breast cancer that essentially reframes the conventional sequential diagnosis-then-treatment modality into conjoined real-time monitoring and adaptively modulated therapeutic delivery systems1. These advanced multifunctional platforms obtain extraordinary targeting specificity through a combination of passive Enhanced Permeability and Retention (EPR) and active receptor-ligand interaction-driven targeting, allowing for preferred tumor accumulation and reduced system-wide toxicity, and current systems have the capability of identifying treatment response 4-6 months prior to conventional approaches. The addition of artificial intelligence has transformed the design of nanotheranostics, and machine learning-based guiding for platforms has achieved extraordinary 15-fold enhanced cellular uptake efficiency through as few as two design iterations, while the multimode imaging functions offer hitherto unprecedented real-time feedback for therapeutic efficacy and resistance occurrence. Despite huge challenges encompassing manufacturing scalability, regulatory complexities, and concerns for biocompatibility, the proof of clinical utility through FDA-approved formulations like Doxil® and Abraxane®, alongside emerging technologies like biomimetic cell membrane-veneered nanoparticles illustrating >81% genome editing efficacy in triple-negative breast cancer and >36-hour circulation times, highlights the game-changer potential of these precision oncology platforms. The projected global nanomedicine market growth from $335.25 billion in 2024 to $594.63 billion by 2028 reflects the revolutionary impact of nanotheranostics in realizing Paul Ehrlich's century-old "magic bullet" concept through the convergence of nanotechnology, artificial intelligence, and personalized medicine to deliver truly adaptive, precision-guided cancer care that promises to revolutionize breast cancer outcomes with enhanced diagnostic accuracy, improved therapeutic efficacy, and dramatically reduced treatment-related toxicity for patients worldwide.

Acknowledgement

The authors would like to express their sincere gratitude to *Deep Science Publisher* and the editorial team of this book for their invaluable support in the final publication process and for providing the opportunity to contribute to this esteemed volume.

Conflicts of Interest

The authors declare that there are no conflicts of interest related to this work.

Funding Source

No funding was received for the preparation of this book chapter.

Author Contribution

All authors have contributed equally to the conception, preparation, and completion of this book chapter.

References

Kim, T. H., Lee, S., & Chen, X. (2013). Nanotheranostics for personalized medicine. *Expert Review of Molecular Diagnostics, 13*(3), 257–269. https://doi.org/10.1586/erm.13.15

Roma-Rodrigues, C., Pombo, I., Raposo, L., Pedrosa, P., Fernandes, A. R., & Baptista, P. V. (2019). Nanotheranostics targeting the tumor microenvironment. *Frontiers in Bioengineering and Biotechnology, 7*, 197. https://doi.org/10.3389/fbioe.2019.00197

Vasseur, R. (2024). Real time monitoring of drug delivery systems innovations and applications, 15(11).

World Health Organization. (2024, February 1). Global cancer burden growing, amidst mounting need for services. World Health Organization. https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services

Fumagalli, C., & Barberis, M. (2021). Breast cancer heterogeneity. Diagnostics, 11(9), 1555. https://doi.org/10.3390/diagnostics11091555

Nissan, N., *et al*. (2024). Diagnostic accuracy of screening contrast-enhanced mammography for women with extremely dense breasts at increased risk of breast cancer. Radiology, 313(1), e232580. https://pubs.rsna.org/doi/10.1148/radiol.232580

Philpotts, L. E., Grewal, J. K., Horvath, L. J., Giwerc, M. Y., Staib, L., & Etesami, M. (2024). Breast cancers detected during a decade of screening with digital breast tomosynthesis: Comparison with digital mammography. Radiology, 312(3), e232841. https://doi.org/10.1148/radiol.232841

Negrão de Figueiredo, G., Mueller-Peltzer, K., Armbruster, M., Rübenthaler, J., & Clevert, D. A. (2019). Contrast-enhanced ultrasound (CEUS) for the evaluation of gallbladder diseases in comparison to cross-sectional imaging modalities and histopathological results. Clinical Hemorheology and Microcirculation. https://doi.org/10.3233/CH-189404

H. Brouwers *et al*., "First-time imaging of [89Zr] trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner," Eur J Nucl Med Mol Imaging, vol. 49, no. 10, pp. 3593–3595, Aug. 2022, doi: 10.1007/s00259-022-05777-x.

Zaikova, E., Cheng, B. Y. C., Cerda, V., & others. (2024). Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment. NPJ Breast Cancer, 10(1), 3. https://doi.org/10.1038/s41523-023-00607-1

Dos Santos, S. N., & Witney, T. H. (2025). Molecular imaging of cancer stem cells and their role in therapy resistance. Journal of Nuclear Medicine, 66(1), 14–19. https://doi.org/10.2967/jnumed.124.267657

Bonlawar, J., *et al*. (2024). Targeted nanotheranostics: Integration of preclinical MRI and CT in the molecular imaging and therapy of advanced diseases. Nanotheranostics, 8(3), 401–426. https://doi.org/10.7150/ntno.95791

Ming, Y., *et al*. (2020). Progress and future trends in PET/CT and PET/MRI molecular imaging approaches for breast cancer. Frontiers in Oncology, 10, Article 1301. https://doi.org/10.3389/fonc.2020.01301

Sommer, A., *et al*. (2024). Radiation exposure and screening yield by digital breast tomosynthesis compared to mammography: Results of the TOSYMA Trial breast density related. European Radiology, 35(1), 166–176. https://doi.org/10.1007/s00330-024-10847-9

Goh, Y., *et al*. (2024). Ultrasound-guided photoacoustic (US-PA) tomography of the breast: Biochemical differentiation using intrinsic tissue markers—lipids, collagen and hemoglobin with histopathologic correlation. Scientific Reports, 14(1), 18054. https://doi.org/10.1038/s41598-024-65114-0

Wang, F., *et al*. (2023). A multifunctional, highly biocompatible, and double-triggering caramelized nanotheranostic system loaded with Fe3O4 and DOX for combined chemo-photothermal therapy and real-time magnetic resonance imaging monitoring of triple negative breast cancer. International Journal of Nanomedicine, 18, 881–897. https://doi.org/10.2147/IJN.S393507

Shamir, S. B., Sasson, A. L., Margolies, L. R., & Mendelson, D. S. (2024). New frontiers in breast cancer imaging: The rise of AI. Bioengineering, 11(5), 451. https://doi.org/10.3390/bioengineering11050451

Xue, X., *et al*. (2018). Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nature Communications, 9(1), 3653. https://doi.org/10.1038/s41467-018-06093-5

Kulkarni, A., *et al*. (2016). Reporter nanoparticle that monitors its anticancer efficacy in real time. Proceedings of the National Academy of Sciences of the United States of America, 113(15). https://doi.org/10.1073/pnas.1603455113

Yang, Y.-S. S., *et al*. (2017). High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry. Nature Communications, 8(1), 14069. https://doi.org/10.1038/ncomms14069

Moss, D. M., & Siccardi, M. (2014). Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. British Journal of Pharmacology, 171(17), 3963–3979. https://doi.org/10.1111/bph.12604

Dhandapani, R., Sethuraman, S., Krishnan, U. M., & Subramanian, A. (2023). Self-assembled multifunctional nanotheranostics against circulating tumor clusters in metastatic breast cancer. Acta Pharmaceutica Sinica B, 13(4), 1711–1725. https://doi.org/10.1016/j.apsb.2022.12.003

Li, X., Zhang, X., Zheng, Y., Wang, J., Yang, G., & Chen, H. (2016). Multimodality imaging in nanomedicine and nanotheranostics. Cancer Biology & Medicine, 13(3), 339–348. https://doi.org/10.20892/j.issn.2095-3941.2016.0055

Tao, Y., Wang, Y., Chen, X., Zhao, Y., Li, H., & Liu, J. (2022). Sequence-activated fluorescent nanotheranostics for real-time profiling pancreatic cancer. JACS Au, 2(1), 246–257. https://doi.org/10.1021/jacsau.1c00553

Mastrantoni, L., Rossi, A., Bianchi, M., Kumar, S., & Lee, J. (2024). Abstract PO2-01-14: Development of artificial intelligence-based machine learning models for predicting survival in hormone-receptor-positive/HER2-negative early breast cancer undergoing neoadjuvant chemotherapy. Cancer Research, 84(9_Supplement), PO2-01-14. https://doi.org/10.1158/1538-7445.SABCS23-PO2-01-14

Elahi, R., & Nazari, M. (2024). An updated overview of radiomics-based artificial intelligence (AI) methods in breast cancer screening and diagnosis. Radiological Physics and Technology, 17(4), 795–818. https://doi.org/10.1007/s12194-024-00842-6

Cavazos, T. B., Patel, R., Kim, S., Lee, D., & Johnson, M. (2024). Harnessing cell-free orphan non-coding RNAs as a predictive measure of long-term survival in neoadjuvant breast cancer therapy. Journal of Clinical Oncology, 42(16_suppl), 585. https://doi.org/10.1200/JCO.2024.42.16_suppl.585

Ortiz-Perez, A., Van Tilborg, D., Van Der Meel, R., Grisoni, F., & Albertazzi, L. (2024). Machine learning-guided high throughput nanoparticle design. Digital Discovery, 3(7), 1280–1291. https://doi.org/10.1039/D4DD00104D

Choi, J.-W., Park, H., Lim, S., Wang, Y., & Chen, Z. (2024). Automated digital oncologic data review for breast cancer research: AI-enabled mCODE and field-of-interest extraction framework. Journal of Clinical Oncology, 42(16_suppl), e12647. https://doi.org/10.1200/JCO.2024.42.16_suppl.e12647

Yu, Y., Zhang, L., Huang, P., Li, M., & Zhao, F. (2024). Multimodal data fusion AI model uncovers tumor microenvironment immunotyping heterogeneity and enhanced risk stratification of breast cancer. MedComm, 5(12), e70023. https://doi.org/10.1002/mco2.70023

Graetz, I., *et al*. (2024). Remote monitoring app for endocrine therapy adherence among patients with early-stage breast cancer: A randomized clinical trial. JAMA Network Open, 7(6), e2417873. https://doi.org/10.1001/jamanetworkopen.2024.17873

Ghosh, S., Abushukair, H. M., Ganesan, A., Pan, C., Naqash, A. R., & Lu, K. (2024). Harnessing explainable artificial intelligence for patient-to-clinical-trial matching: A proof-of-concept pilot study using phase I oncology trials. PLoS ONE, 19(10), e0311510. https://doi.org/10.1371/journal.pone.0311510

Obeagu, E. I., & Obeagu, G. U. (2024). Predictive models and biomarkers for survival in stage III breast cancer: A review of clinical applications and future directions. Annals of Medicine & Surgery, 86(10), 5980–5987. https://doi.org/10.1097/MS9.0000000000002517

Mankoff, D. A., Edmonds, C. E., Farwell, M. D., & Pryma, D. A. (2016). Development of companion diagnostics. Seminars in Nuclear Medicine, 46(1), 47–56. https://doi.org/10.1053/j.semnuclmed.2015.09.002

Chen, S., *et al*. (2024). Abstract 1157: Molecular signatures associated with the progression from DCIS to IDC. Cancer Research, 84(6_Supplement), 1157. https://doi.org/10.1158/1538-7445.AM2024-1157

Porfírio De Aguiar, M. (2023). Pharmacogenomics in tailoring first-line therapy for breast cancer: PharmGKB database insights. Oncology. https://doi.org/10.1101/2023.11.28.23299155

Roberts, R. (2018). Genetic risk stratification: Tipping point for global primary prevention of coronary artery disease. Circulation, 137(24), 2554–2556. https://doi.org/10.1161/CIRCULATIONAHA.118.034732

Lindsay, J. R., *et al*. (2025). Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment. Cancer Biology. https://doi.org/10.1101/2025.03.05.641733

Sivapiragasam, A., *et al*. (2021). Predictive biomarkers for immune checkpoint inhibitors in metastatic breast cancer. Cancer Medicine, 10(1), 53–61. https://doi.org/10.1002/cam4.3550

Karsten, M. M., *et al*. (2021). PRO B: Evaluating the effect of an alarm-based patient-reported outcome monitoring compared with usual care in metastatic breast cancer patients—Study protocol for a randomised controlled trial. Trials, 22(1), 666. https://doi.org/10.1186/s13063-021-05642-6

Priskin, K., *et al*. (2021). BC-Monitor: Towards a routinely accessible circulating tumor DNA-based tool for real-time monitoring breast cancer progression and treatment effectiveness. Cancers, 13(14), 3489. https://doi.org/10.3390/cancers13143489